Low incidence of hepatitis <scp>B</scp> e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice

Abstract

The HBeAg seroconversion rate seen in clinical settings for oral nucleos(t)ides appears much lower than those reported in pivotal trials, especially in patients with lower ALT and higher HBV DNA levels. HBeAg-positive patients should be counseled about the high possibility of the long treatment duration required to achieve recommended treatment end-points.